_570_850.jpg "Alembic Pharmaceuticals Gets USFDA Nod To Market Generic Tablet For Atrial Fibrillation")
_630_630.jpg)
Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market generic Dronedarone tablets, which is used to reduce the risk of hospitalisation for atrial fibrillation, in the American market.
The company has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for its medication in the strength of 400 mg, the drugmaker said in a statement.
The tentatively approved ANDA is therapeutically equivalent to Sanofi-Aventis' Reference Listed Drug (RLD) product Multaq Tablets, 400 mg.
Dronedarone is indicated to reduce the risk of hospitalisation for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation.
Cumulatively, the company has so far received 158 ANDA approvals from USFDA.
_140_196.jpg)
Sunteck Realty Sales Bookings Surge Marginally To Rs 352 Crore In Q3 _250_425.jpg "Sunteck Realty Sales Bookings Surge Marginally To Rs 352 Crore In Q3")
_200_320.jpg "Let it Snow, Let it Snow, Let it Snow")
